Ovarian Cancer Clinical Pipeline | 180+ Companies Driving the Next Wave of Innovation

The Ovarian Cancer market is evolving with cutting-edge research and new therapeutic advancements.

DelveInsight's 'Ovarian Cancer Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Ovarian Cancer therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Ovarian Cancer pipeline domain.

For Ovarian Cancer emerging drugs, the Ovarian Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Ovarian Cancer Pipeline Report
• DelveInsight's Ovarian Cancer Pipeline analysis depicts a robust space with 180+ active players working to develop 200+ pipeline drugs for Ovarian Cancer treatment.
• The leading Ovarian Cancer companies include Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-La Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others are evaluating their lead assets to improve the Ovarian Cancer treatment landscape.
• Key Ovarian Cancer pipeline therapies in various stages of development include Avutometinib (Vs-6766) + Defactinib (Vs-6063), Relacorilant (Cort125134), Imfinzi (Durvalumab), Raludotatug Deruxtecan (R-Dxd/Ds-6000a), Olvimulogene Nanivacirepvec (Olvi-Vec), Nemvaleukin Alfa (Alks 4230), Catequentinib (Anlotinib/Al3818), Raludotatug Deruxtecan (R-Dxd/Ds-6000a), Luveltamab Tazevibulin (Stro-002), Atezolizumab, Tisotumab Vedotin, SON-1010, and others.
• In February 2025, the FDA granted fast track designation to CUSP06, a CDH6-directed antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer.
• In February 2025, Gradalis, Inc. announced that the FDA granted RMAT designation for its personalized immunotherapy, Vigil® (Gemogenovatucel-T), based on positive results from the Phase 2b VITAL trial. Vigil is being developed as a maintenance treatment for women with advanced Stage IIIb/IV ovarian cancer who are HRP, have high clonal tumor mutation burden, and are in complete response after surgery and chemotherapy.
• In January 2025, Gameto, a clinical-stage biotech company focused on iPSC-based therapies for women's health, announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for Fertilo. This approval enables the launch of the first U.S.-based Phase 3 clinical trial for an iPSC-based therapy, marking a significant milestone in addressing unmet needs in reproductive medicine.
• In December 2024, Verastem Oncology announced the FDA's acceptance of its New Drug Application (NDA) for avutometinib, a RAF/MEK clamp, combined with defactinib, a FAK inhibitor, under the accelerated approval pathway for treating KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) in adults after prior systemic therapy.

Request a sample and discover the recent breakthroughs happening in the Ovarian Cancer pipeline landscape @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ovarian Cancer Overview
Ovarian cancer is the leading cause of death among women diagnosed with gynecological cancers and ranks as the fifth most common cause of cancer-related mortality in women overall. A major challenge in managing this disease is that most cases are diagnosed at an advanced stage, significantly reducing survival outcomes. Existing screening tests have low predictive value, further complicating early detection. While a detailed gynecological evaluation, transvaginal ultrasound, and cancer antigen-125 (CA-125) assay are commonly used in early detection efforts, they have not significantly reduced ovarian cancer morbidity or mortality.

Epithelial ovarian cancer is classified into four main histological types: serous, endometrioid, clear cell, and mucinous tumors, with rare subtypes like Brenner and seromucinous tumors. Further classification divides ovarian cancer into Type I and Type II tumors, with Type II being more aggressive and often linked to continuous ovarian cycles, inflammation, and endometriosis. Type I tumors, including low-grade serous, endometrioid, clear-cell, and mucinous carcinomas, usually present at an early stage, have low proliferative activity and carry a better prognosis. In contrast, Type II tumors-which include high-grade serous carcinoma, carcinosarcoma, and undifferentiated carcinoma-tend to be high grade, aggressive, and diagnosed at an advanced stage, exhibiting high chromosomal instability and frequent p53 mutations.

The standard treatment approach for ovarian cancer consists of surgery and platinum-based chemotherapy. However, in the past decade, targeted therapies like anti-angiogenic bevacizumab and Poly (ADP-ribose) polymerase (PARP) inhibitors have become increasingly significant in treatment strategies. Despite initial responses, a high recurrence rate remains a major challenge, with many relapsed cases proving less responsive to treatment and associated with a higher risk of treatment failure. Therefore, developing effective prevention and early detection strategies, alongside novel therapeutic approaches based on molecular characterization, is essential to improving ovarian cancer outcomes.

Find out more about Ovarian Cancer medication @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ovarian Cancer Treatment Analysis: Drug Profile
Atezolizumab: Genentech
Atezolizumab is a humanized kappa immunoglobulin (Ig) G1 monoclonal antibody consisting of two heavy chains (448 amino acids) and two light chains (214 amino acids) and is produced in Chinese hamster 0vary cells. Atezolizumab was engineered to eliminate Fc-effector function via a single amino acid substitution (asparagine to alanine) at position 298 on the heavy chain, which results in a non-glycosylated antibody that has minimal binding to Fc receptors and, consequently, eliminates detectable Fc-effector function and depletion of cells expressing programmed death-ligand 1 (PD-L1) in humans. Atezolizumab targets human PD-L1 and inhibits its interaction with its receptors, programmed death-1 (PD-1) and B7.1, both of which can provide inhibitory signals to T cells. The drug is currently in phase 3 of clinical trials for the treatment of Ovarian Cancer.

Tisotumab Vedotin: Genmab
Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis. Tisotumab vedotin includes an antibody targeting TF conjugated with monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. The drug is currently in phase 2 of clinical trials for the treatment of Ovarian Cancer.

SON-1010: Sonnet Biotherapeutics
SON-1010 is a proprietary version of native human IL-12, configured using Sonnet's fully human albumin binding (FHAB®) platform, which targets the tumor microenvironment (TME) and extends the pharmacokinetics (PK) and subsequent pharmacodynamics (PD) of the molecule. Sonnet and Roche have entered into a Master Clinical Trial and Supply Agreement (MCSA), along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer (PROC) patient setting. Currently the drug is in the Phase I/II stage of its development for the treatment of ovarian cancer.

Key Ovarian Cancer Therapies and Companies
• Avutometinib (Vs-6766) + Defactinib (Vs-6063): Verastem Oncology
• Relacorilant (Cort125134): Corcept Therapeutics
• Imfinzi (Durvalumab): Astrazeneca
• Raludotatug Deruxtecan (R-Dxd/Ds-6000a): Daiichi Sankyo And Merck
• Olvimulogene Nanivacirepvec (Olvi-Vec): Genelux Corporation
• Nemvaleukin Alfa (Alks 4230): Mural Oncology
• Catequentinib (Anlotinib/Al3818): Advenchen Laboratories
• Raludotatug Deruxtecan (R-Dxd/Ds-6000a): Daiichi Sankyo And Merck
• Luveltamab Tazevibulin (Stro-002): Sutro Biopharma
• Atezolizumab: Genentech
• Tisotumab Vedotin: Genmab
• SON-1010: Sonnet Biotherapeutics

Learn more about the novel and emerging Ovarian Cancer pipeline therapies @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ovarian Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Ovarian Cancer Pipeline Report
• Coverage: Global
• Key Ovarian Cancer Companies: Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-La Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others.
• Key Ovarian Cancer Pipeline Therapies: Avutometinib (Vs-6766) + Defactinib (Vs-6063), Relacorilant (Cort125134), Imfinzi (Durvalumab), Raludotatug Deruxtecan (R-Dxd/Ds-6000a), Olvimulogene Nanivacirepvec (Olvi-Vec), Nemvaleukin Alfa (Alks 4230), Catequentinib (Anlotinib/Al3818), Raludotatug Deruxtecan (R-Dxd/Ds-6000a), Luveltamab Tazevibulin (Stro-002), Atezolizumab, Tisotumab Vedotin, SON-1010, and others.

Dive deep into rich insights for drugs used for Ovarian Cancer treatment; visit @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Ovarian Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Ovarian Cancer Pipeline Therapeutics
6. Ovarian Cancer Pipeline: Late-Stage Products (Phase III)
7. Ovarian Cancer Pipeline: Late-Stage Products (Phase III)
8. Ovarian Cancer Pipeline: Mid-Stage Products (Phase II)
9. Ovarian Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.